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The African swine fever virus (ASFV) causes a fatal hemorrhagic disease in domestic swine, and at present no treatment or vac-
cine is available. Natural and gene-deleted, live attenuated strains protect against closely related virulent strains; however, they
are yet to be deployed and evaluated in the field to rule out chronic persistence and a potential for reversion to virulence. Previ-
ous studies suggest that antibodies play a role in protection, but induction of cytotoxic T lymphocytes (CTLs) could be the key to
complete protection. Hence, generation of an efficacious subunit vaccine depends on identification of CTL targets along with a
suitable delivery method that will elicit effector CTLs capable of eliminating ASFV-infected host cells and confer long-term pro-
tection. To this end, we evaluated the safety and immunogenicity of an adenovirus-vectored ASFV (Ad-ASFV) multiantigen
cocktail formulated in two different adjuvants and at two immunizing doses in swine. Immunization with the cocktail rapidly
induced unprecedented ASFV antigen-specific antibody and cellular immune responses against all of the antigens. The robust
antibody responses underwent rapid isotype switching within 1 week postpriming, steadily increased over a 2-month period,
and underwent rapid recall upon boost. Importantly, the primed antibodies strongly recognized the parental ASFV (Georgia
2007/1) by indirect fluorescence antibody (IFA) assay andWestern blotting. Significant antigen-specific gamma interferon-posi-
tive (IFN-) responses were detected postpriming and postboosting. Furthermore, this study is the first to demonstrate induc-
tion of ASFV antigen-specific CTL responses in commercial swine using Ad-ASFVmultiantigens. The relevance of the induced
immune responses in regard to protection needs to be evaluated in a challenge study.
African swine fever (ASF) is a highly contagious and fatal hem-orrhagic swine disease. It has case morbidity and mortality
rates that approach 100% (1). Swine that recover become carriers
and shed the virus for up to 70 days (2). There is no treatment or
vaccine available, and the only control strategy in case of an
outbreak is quarantine and removal of infected and in-contact
animals. The ASF causes economic losses worldwide and se-
verely affects the pork industry in sub-Saharan Africa where it
is endemic (3).
The pathogen, African swine fever virus (ASFV), is a double-
stranded DNA enveloped icosahedral arbovirus belonging to the
genus Asfivirus and the only member in the family Asfarviridae (4).
ASFV has a 170- to 190-kb nonsegmented genome containing 150
to 167 open reading frames (ORFs) (5, 6). The ASFV has a natural
sylvatic transmission cycle between Ornithodoros tick species and
wild suids such as warthogs (3). Infections in wild suids are
asymptomatic and persistent, leading to a carrier state and trans-
mission to domestic pigs, which hinders eradication.
Although an effective ASFV vaccine has not yet been devel-
oped, the fact that swine exposed to less virulent isolates (naturally
or experimentally attenuated) are protected when challenged with
homologous or closely related virulent isolates suggests that vac-
cine development is possible (7–9). Published data suggest that
antibodies and T cells play critical roles in virus control (9–16).
ASFV-infected convalescent swine serum can neutralize the infec-
tivity of homologous and some heterologous strains in vitro and in
vivo, possibly by inhibiting virus attachment and internalization
(16–19). Generally, anti-ASFV antibodies are detectable from
about 6 days postinfection, and if the animal survives, antibodies
may persist for long periods. However, despite the presence of
antibodies, virus neutralization may not occur. Thus, the specific
role of antibodies in ASFV protection is not yet fully understood
(20). The importance of cytotoxic T lymphocytes (CTLs) in pro-
tection against ASFV has been demonstrated in a number of stud-
ies. Importantly, in vivo depletion of CD8 T cells decreases pro-
tection against ASFV in swine, and in vitro studies indicate that
there is preferential proliferation of CD8 T cells in the presence
of live virus, whereas both CD4 and CD8 T cells are stimulated
by UV-inactivated virus (14, 21). In addition, ASFV-specific CTL
activity is detected in swine infected with nonlethal ASFV isolates
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(9, 10, 12, 13). The requirement for CTLs in protection is further
supported by the observation that adjuvant-formulated killed
ASFV and recombinant vaccine candidate antigens that induce
high antibody responses do not confer solid protection, and these
outcomes strongly suggest that major histocompatibility complex
(MHC) class I presentation of ASFV antigens is critical (15, 22–
25). In addition, it has been observed that swine that generate high
antibody titers but low cellular responses following immunization
with a live attenuated virus develop chronic disease (26).
Although a vaccine using live attenuated ASFV can protect
swine against the disease, it is not an ideal vaccine due to the
potential risk of vaccine virus persistence and reversion to viru-
lence. Additionally, a live, naturally attenuated ASFV vaccine used
in Portugal in the 1960s resulted in severe immune-mediated
postvaccination reactions in immunized animals, precluding any
further use during outbreaks (27). Subunit vaccines based on
some of the most extensively studied ASFV antigens, such as p32,
p54, and p72 envelope protein, have shown some promise. These
antigens, among others, have been tested as vaccine candidates
either as baculovirus-expressed recombinant proteins or via DNA
plasmid delivery (15, 22–25). Delayed onset of viremia, delayed
mortality, and partial protection have been observed in most of
these studies, which suggest that these antigens do play a role in
protection but are not capable of conferring complete protection
when they are used singly or in combination. Thus, it is envisaged
that development of an efficacious vaccine requires empirical
identification of multiple ASFV antigens formulated in a suitable
delivery system that can successfully induce robust immunity.
Given that one or a combination of a few subunit antigens has
not been able to confer complete protection so far, we set out to
test the ability of a live-vectored ASFV multiantigen cocktail to
elicit strong CTL, gamma interferon (IFN-)-secreting T cell, and
B cell responses. We selected a replication-deficient human ade-
novirus (Ad5) vector as the antigen delivery platform for several
reasons, such as safety, high transgene expression, and scalability
(28–32). Additionally, adenovirus-vectored vaccines have been
shown to induce stronger CTL responses than vaccinia virus, plas-
mid DNA, or a combination of these two (33). To test our ap-
proach, we used p32, p54, and p72 antigens since they are well
characterized. Furthermore, antigens p32 and p72 have been pre-
viously identified as CTL targets (10, 12). We also included poly-
protein pp62, which is a major component of the core shell, is
essential for viral core development, and is very strongly recog-
nized by ASFV-specific convalescent-phase serum (34). We tested
this multiantigen (four-way) cocktail in a prime-boost regimen
using two different adjuvant formulations and at two different
immunizing doses.
MATERIALS AND METHODS
Generation of plasmid constructs encoding ASFV antigens. The ASFV
p32, p54, pp62 polyprotein (pp62), and p72 amino acid sequences based
on the epidemiologically relevant Georgia 2007/1 isolate (GenBank acces-
sion no. FR682468) were modified to add, in frame, a FLAG and hemag-
glutinin (HA) tag at the N and C termini, respectively. This allowed the
use of one primer pair to move the expression cassettes of all antigens
across multiple expression vectors, in addition to the use of the tags for
tracking protein expression and affinity purification of recombinant pro-
teins. The resultant amino acid sequences of the ASFV antigens were used
to design synthetic genes codon optimized for protein expression in the
swine host. Codon optimization, gene synthesis, cloning into pUC57, and
gene sequence validation were outsourced (GenScript). Each gene was
then subcloned into pcDNA3.3-TOPO TA, pAd/CMV/V5-DESTGate-
way, and pFastBac HBM TOPO vectors (Invitrogen) to generate DNA
plasmid constructs for protein expression in mammalian cells, generation
of recombinant adenoviruses, and generation of recombinant baculovi-
ruses, respectively, using the manufacturer’s protocols. The constructs
generated were validated by DNA sequencing.
Generation of virus constructs encoding ASFV antigens. The pAd
constructs were used to generate recombinant replication-incompetent
adenoviruses using a ViraPower Adenoviral Expression System (Invitro-
gen). Following validation of protein expression by immunocytometric
analysis, the recombinant adenoviruses were scaled up to generate virus
for immunizations. Virus titers (infectious focus units [IFU]) were deter-
mined using a QuickTiter Adenovirus Titer Immunoassay kit (VPK-109;
Cell Biolabs) with a minor modification. We used purified rabbit
anti-adenovirus polyclonal IgGs (1:500 dilution) (made in-house) as
the primary antibody, followed by an alkaline phosphatase-conjugated
anti-rabbit IgG (1:1,000) (catalog number 711-055-152; Jackson Immuno-
Research) as the secondary antibody and Fast Red TR/Naphthol AS-MX
as the substrate (F4523; Sigma). A recombinant adenovirus expressing
luciferase (Ad-Luc) was similarly scaled up and titrated to serve as the
negative-control immunogen. To generate recombinant baculoviruses,
pFastBac constructs were used to generate bacmids which were subse-
quently transfected into Sf-9 cells. One clone of each baculovirus was
scaled up, the titer was determined, and then the clone was used to infect
High-Five cells (Invitrogen) to generate FLAG-tagged recombinant pro-
teins, which were affinity purified with anti-FLAG M2 affinity gel (A2220;
Sigma). Recombinant pp62 was generated using an HEK 293 Freestyle
Expression system (Invitrogen).
Evaluation of protein expression. Protein expression by the plasmid
constructs and by the recombinant viruses encoding the ASFV antigens
was validated by immunocytometric analysis as previously described (35).
Briefly, HEK 293A cell monolayers transfected with the plasmid con-
structs or infected with the recombinant adenoviruses were probed with
mouse anti-FLAG M2-alkaline phosphatase conjugate (Sigma, St. Louis,
MO) diluted 1:1,000 in blocking buffer (phosphate-buffered saline [PBS]
with 5% fetal bovine serum). Duplicate transfected or infected HEK 293A
cell monolayers were first incubated with a 1:500 dilution of gamma-
irradiated convalescent swine serum. (Several ASFV isolates were used to
produce the convalescent-phase serum from a donor pig that was sequen-
tially infected with a series of tissue culture-adapted and wild-type viruses
from p72 genotypes I [DR11, Haiti 81, Lisbon 60, Malawi 83, and UG-61],
VIII, and X. The serum was a kind gift from E. J. Kramer, Plum Island
Animal Disease Center.) The cell monolayers were then probed with a
1:1,000 dilution of alkaline phosphatase-conjugated goat anti-porcine
IgG (6050-04; Southern Biotech). The alkaline phosphatase activity was
then detected using Fast Red TR/Naphthol AS-MX substrate (F4523;
Sigma). Mock-transfected/infected cells served as negative controls. Pro-
tein expression by the generated recombinant baculoviruses was similarly
evaluated by probing infected Sf-9 cells.
Immunization of swine. Twenty weaned piglets (30 lb) were
acquired, and during the quarantine period commercial vaccines were
used against defined pathogens to meet institutional requirements. Three
groups of piglets (n 5) were immunized with a cocktail of the recombi-
nant adenoviruses expressing ASFV antigens formulated in defined adju-
vants (ENABL from BenchMark Biolabs and an experimental adjuvant
from Zoetis) (Table 1). Sham-infected control piglets (n 5) were inoc-
ulated with an equivalent amount of the Ad-Luc virus (Table 1). The
inoculum was administered intramuscularly in the neck region behind
the ears. Fourteen weeks postpriming, the animals were boosted with the
cognate priming dose and adjuvant. The pigs were terminated at a rate of
one group a week starting at 8 weeks postboost.
ELISA. A direct enzyme-linked immunosorbent assay (ELISA) was
used to evaluate antigen-specific antibody responses as previously de-
scribed (35). Briefly, microplates coated with 100l of 1g/ml of affinity-
purified antigen in bicarbonate coating buffer were first incubated with
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100 l of serum (diluted at 1:100) in triplicates, followed by incubation
with 100l of peroxidase-conjugated anti-swine IgG (114-035-003; Jack-
son ImmunoResearch) (1:5,000 dilution). The plates were developed us-
ing Sure Blue Reserve TMB (3,3=,5,5=-tetramethylbenzidine) substrate
(53-00-02; KPL), and the reaction was stopped using 1 N hydrochloric
acid. The optical density (OD) at 450 nm was then determined using a
microplate reader. To determine antigen-specific IgM responses in serum
from blood collected at week 1 postpriming, horseradish peroxidase
(HRP)-conjugated anti-swine IgM (1:10,000) (A100-100P; Bethyl Labo-
ratories) was used as the secondary antibody. Antigen-specific IgG end-
point titers were determined for serum from blood collected week 1 post-
boost by making a range of 2-fold serum dilutions starting at 1:1.6 104
to 1:1.6 107. Similarly diluted preimmunization sera served as cognate
controls. The titer was then determined to be the dilution of the postboost
serum for which the mean of the OD was higher than the mean plus 3
times the standard deviation of the cognate preimmunization serum. The
significance of the difference in antigen-specific IgG titers among the
groups was determined by analysis of variance (ANOVA), followed by
Tukey’s multiple-comparison test, and a P value of0.05 was considered
significant.
IFA assay. Teflon-coated slide wells (63425-05; Electron Microscopy
Sciences) were pretreated by incubation with 300g/ml of rat tail collagen
(354249; Corning) in Dulbecco’s phosphate-buffered saline (DPBS)
(14190-144; Invitrogen) for 1 h at 37°C, oven drying for 30 min, and
incubation overnight in a biosafety cabinet (15 cm from UV light). Pri-
mary monocytes/macrophages were isolated from whole swine blood as
previously described (36) and infected with ASFV (Georgia 2007/1) at a
multiplicity of infection (MOI) of 1 for 1 h at 37°C. Approximately 4 
105 infected cells and also mock-infected cells were then added to the wells
of the pretreated Teflon slides (25 l/well). The slides were incubated
overnight at 37°C at 5% CO2, fixed with a chilled (20°C) solution con-
taining acetone and methanol (1:1) for 10 min, and stored at70°C until
required. To carry out the indirect fluorescence antibody (IFA) assay, the
slides were incubated with blocking solution (5% nonfat dry milk, 2%
horse serum, 2% calf serum, 2% fetal calf serum, and 5% bovine serum
albumin [BSA] in DPBS) for 30 min in a humidified chamber at 37°C.
After a blocking step, the infected and mock-infected wells were incubated
with 1:20, 1:100, and 1:200 dilutions of serum (week 1 postboost) in
blocking buffer for 1 h at 37°C. ASFV-specific convalescent-phase serum
(1:500) was used as a positive control, and normal swine serum (Gibco)
was used as a negative control. Following three rinses with DPBS, the wells
were then incubated with fluorescein isothiocyanate (FITC)-conjugated
goat anti-swine serum (02-14-02; Kirkegaard and Perry) for 45 min at
37°C. The wells were rinsed similarly again and mounted with Prolong
Gold antifade reagent with 4=,6=-diamidino-2-phenylindole ([DAPI]
PT389868; Invitrogen). The results observed at a 1:20 serum dilution are
represented in Fig. 5A, and the results of 1:200 serum dilutions are sum-
marized in Table 2. The IFA assays were conducted at Plum Island Animal
Disease Center.
Western blotting. Swine serum from week 1 postboost were blotted
against cell lysates prepared from Georgia 2007/1 ASFV (Vero cell
adapted)-infected Vero cells (ATCC CCL-81). Briefly, ASFV-infected
Vero cells exhibiting cytopathic effect (CPE) at 72 h postinfection were
harvested by centrifugation, lysed in mammalian protein extraction re-
agent (M-PER) (78501; Thermo Scientific), mixed 1:1 with 2NuPAGE
lithium dodecyl sulfate (LDS) sample buffer, boiled, electrophoresed on a
NuPAGE 4 to 12% bis-Tris gel for 35 min, and transferred to 0.2-m-
pore-size polyvinylidene difluoride (PVDF) membranes (LC2002; Invit-
rogen). Following blocking in phosphate-buffered saline with Tween 20
(PBST) containing 5% nonfat dry milk, membranes were transferred to a
Protean II Slot-Blotter and incubated with serum diluted 1:50 in blocking
buffer in individual wells. The membranes were then removed from the
blotting apparatus and incubated with goat anti-swine HRP (14-14-06;
KPL) diluted 1:2,000 in blocking buffer for 1 h. The blots were developed
by exposure to diaminobenzidine (DAB) substrate (D4293; Sigma). ASFV-
specific convalescent-phase serum (1:10,000) was used as a positive con-
trol, and normal swine serum was used as a negative control (1:200). A
similar blotting experiment was carried out using mock-infected cell ly-
sates to gauge background reactivity to host cell antigens. The Western
blotting was performed at Plum Island Animal Disease Center.
IFN- ELISPOT assays. The frequencies of antigen-specific IFN--
secreting T cells were determined by an enzyme-linked immunospot
(ELISPOT) assay performed biweekly postpriming and weekly postboost.
The assay was conducted in triplicate wells of MultiScreen-HA plates
TABLE 1 Immunization protocol
Group
(n 5/group) Immunogen
Dose/pig
(IFU) Adjuvant
T1 Ad5-ASFV 4-way cocktail 4 1010a ENABLd
T2 Ad5-ASFV 4-way cocktail 4 1011b ENABL
T3 Ad5-ASFV 4-way cocktail 4 1011b Zoetise
T4 Ad5-Lucc 4 1011 ENABL
a Pool of four Ad5-ASFV constructs, each at 1 1010 IFU (infectious focus units).
b Pool of four Ad5-ASFV constructs, each at 1 1011 IFU.
c Sham inoculation control.
d ENABL adjuvant (Benchmark Biolabs catalog number 7010106-C6).
e Experimental adjuvant (proprietary formulation).
TABLE 2 Summary of IFA assay data
Group and swine no.
or control
Reactivity in ASFV-infected
macrophagesa
T1
33 
35 
36 
40 
42 
T2
34 
41 
43 
46 
48 
T3
31 
37 
93 
94 
96 
T4
32 
38 
39 
44 
45 
Anti-ASFV convalescent-phase serumb 
Normal serumc 
a The reactivity of the serum from each animal was compared to the reactivity of the
positive-control serum (ASFV-specific convalescent-phase serum). The number of plus
signs represents the intensity of the reaction, as follows:, as strong as the
positive-control serum;, weak but positive signal. The minus sign () indicates the
absence of signal. The best response is indicated in boldface. Mock-infected cells
showed no reactivity.
b Positive control.
c Negative control.
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(Millipore) using a Mabtech kit (catalog number 3130-2A), as per the
manufacturer’s instructions and as described previously (35). Briefly,
0.25  106 whole-blood-derived peripheral blood mononuclear cells
(PBMCs) or splenocytes were incubated with affinity-purified antigens
(2.5 g/ml) in 100 l per well of complete RPMI 1640 medium. Phyto-
hemagglutinin (PHA) mitogen (5 g/ml) was used as a positive control,
and medium alone served as a negative control. The spots were quantified
with an ELISPOT reader and AID software (version 3.4; AutoImmun
Diagnostica, Strasburg, Germany). The results were presented as the mean
number of antigen-specific IFN- spot-forming cells per 106 PBMCs after
background medium counts were subtracted. The significance of the dif-
ferences in IFN--positive (IFN-) PBMC responses between each vac-
cinated group (T1, T2, and T3) and control group (T4) was analyzed by
ANOVA, followed by Bonferroni’s multiple-comparison test, and a P
value of0.05 was considered significant.
CTL assays. A standard chromium (51Cr) release assay was used to
measure antigen-specific T cell cytotoxicity as previously described (37).
(i) Generation of effector cells. PBMCs isolated from blood collected
4 weeks postboost were resuspended in RPMI 1640 medium (Lonza) con-
taining 45% Click’s medium (9195; Irvine Scientific), 10% fetal bovine
serum (FBS), 1	-mercaptoethanol, 1GlutaMAX, 50g/ml gentami-
cin, and 1 penicillin-streptomycin (Pen/Strep; GIBCO) at a cell density
of 4  106 cells/ml and distributed in aliquots of 1 ml/well of a 24-well
culture plate. The PBMCs were infected with each of the recombinant
adenoviruses at an MOI of 1,000 for in vitro stimulation of the T cells.
After 10 days, the cells were harvested and centrifuged on a Ficoll gradient
to remove dead cells. The live cells were then washed with PBS, resus-
pended in complete RPMI 1640 medium, and counted to serve as effectors
for the CTL assay.
(ii) Generation of target cells. Prior to immunization, skin biopsy
specimens were taken from each piglet using 4-mm biopsy specimen
punches (3785707; American Screening Corp.). Primary skin fibroblast
cultures were established from these skin tissues as previously described
(38). Briefly, the skin tissues were cut into small pieces under sterile con-
ditions and cultured in 12-well plates containing 1 ml of Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% FBS, 1
GlutaMAX, 50 g/ml gentamicin, and 1 Pen/Strep (Gibco). When the
fibroblasts reached confluence, they were passaged and frozen regularly
until sufficient stocks were generated. Target cells were generated 24 h
prior to the CTL assay by transfecting autologous fibroblasts with the
pcDNA plasmid constructs using Gene-In transfection reagent (GST-
1000; MTI-Global Stem) as per the manufacturer’s instructions. Trans-
fection efficiencies of about 20 to 30% were achieved (predetermined by
immunocytometric analysis). On the day the assay was conducted, the
cells were detached using Accutase, washed with DMEM containing 10%
FBS, labeled with 100 Ci per 106 cells of Na2
51CrO4 (PerkinElmer) for 1
h at 37°C in 5% CO2, washed three times, and resuspended in complete
RPMI 1640 medium for use as targets in the assay.
(iii) Chromium release assay. The effectors and targets were added
at effector/target (E:T) ratios of 50:1 and 25:1 in duplicate wells of 96-well
round-bottom microtiter plates in final volumes of 100 l per well and
incubated at 37°C in 5% CO2 for 6 h. The plate was then centrifuged at
1,000 rpm for 4 min, and supernatants were harvested to measure chro-
mium release in a MicroBeta counter (1450 Liquid Scintillation Counter
and Luminescence Counter; PerkinElmer). Spontaneous release of the
label was measured from supernatants of targets incubated without effec-
tors, and maximum release was measured from targets lysed with 5%
Triton-X. Percent specific lysis was calculated as described previously
(37). Fibroblasts transfected with a construct expressing a chimera of VP1
and 3D polymerase antigens of the foot and mouth disease virus (FMDV)
served as a negative control to assess background lytic activity.
Statistical analysis. All analyses were performed with GraphPad
Prism, version 6.05, and the significance level used was a P value of
0.05.
The antigen-specific IgG titers among the treatment groups were com-
pared using one-way ANOVA, followed by Tukey’s multiple-comparison
test. For all the IFN- ELISPOT assays, the mean IFN- response of treat-
ment groups (T1 to T3) was compared to the mean response of the sham-
FIG 1 Protein expression by ASFV constructs. Protein expression by the constructs encoding ASFV antigens was evaluated by immunocytometric analysis of
HEK 293A cells. (A) Cells transfected with pcDNA3 constructs and probed with anti-FLAG MAb. (B) Cells infected with recombinant adenoviruses and probed
with anti-FLAG MAb. (C) Cells infected with recombinant adenoviruses and probed with gamma-irradiated ASFV-specific convalescent-phase serum. Negative
controls are mock-transfected (A) or mock-infected (B and C) HEK 293A cells.
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treated control group (T4) using one-way ANOVA, followed by Bonfer-
roni’s multiple-comparison test.
Ethics statement. All animal procedures were conducted in accor-
dance with Animal Use Protocol 2012-59, reviewed and approved by the
Texas A&M University Institutional Animal Care and Use Committee
(IACUC) (permit 2009067), which adheres to the regulations, policies,
and guidelines outlined in the Animal Welfare Act (AWA), USDA Animal
Care Resource Guide, and the PHS Policy on Humane Care and Use of
Laboratory Animals. Pigs were monitored twice daily for any clinical signs
and to document any localized and or systemic adverse effects. The ani-
mals were euthanized with an overdose of sodium pentobarbital. A lack of
heartbeat was then confirmed by a stethoscope.
RESULTS AND DISCUSSION
Protein expression by constructs encoding ASFV antigens.
Codon-optimized synthetic genes encoding p32, p54, pp62, and
p72 ASFV antigens fused in frame to FLAG tag were used to gen-
erate pcDNA3 constructs, recombinant adenoviruses, and recom-
binant baculoviruses. Immunocytometric analysis of HEK 293A
cells transfected with the pcDNA3 constructs and probed with an
anti-FLAG monoclonal antibody (MAb) confirmed expression of
each antigen (Fig. 1A). Similarly, HEK 293A cells infected with the
recombinant adenoviruses and probed with anti-FLAG MAb con-
firmed protein expression (Fig. 1B), and in addition, infected cells
probed with the ASFV-specific convalescent-phase serum vali-
dated that the expressed antigens were authentic (Fig. 1C). The
recombinant baculoviruses were used to generate affinity-purified
recombinant ASFV proteins, which were used for ELISA and
IFN- ELISPOT assays. We did not generate recombinant bacu-
lovirus for antigen pp62 since transfection of 293 Freestyle cells
with the pcDNA construct and subsequent purification yielded
sufficient protein for in vitro analyses. The affinity-purified pro-
teins were shown to be authentic by Western blotting using ASFV-
specific convalescent-phase serum (see Fig. S1 in the supplemental
material).
Ad-ASFVmultiantigen cocktail rapidly induced robust anti-
body responses. (i) Postprime response. ELISA evaluation of an-
tigen-specific IgM and IgG antibody responses in serum from
blood collected at 1 week postpriming showed that all the pigs
inoculated with either the 1010 (T1) or 1011 (T2 and T3) Ad-ASFV
multivalent cocktail dose, but not the negative controls (T4), had
seroconverted and mounted robust ASFV antigen-specific anti-
bodies (Fig. 2). More importantly, most pigs underwent isotype
switching within 1 week, based on relatively higher antigen-
specific IgG than IgM antibody responses (Fig. 2). The IgM and
IgG profiles were similar for p32, p54, and pp62 antigens, with no
notable difference between the three treatment groups. However,
compared to the pigs immunized with the ENABL adjuvant (T1
and T2), the pigs immunized using the Zoetis adjuvant (T3)
clearly had higher p72 antibody responses, which were IgM dom-
FIG 2 Ad5-ASFV multiantigen cocktail rapidly primed antibody responses. Antigen-specific IgMs (light shades) and IgGs (dark shades) in serum from week 1
postprime were evaluated by ELISA. The individual animal response to each antigen was evaluated in triplicate and is depicted as the mean of the absorbance
values at 450 nm minus the mean absorbance of cognate preimmune serum. The error bars represent the standard deviation between triplicates. T4, negative
control.
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inant. Biweekly monitoring of antigen-specific IgG responses in
each animal showed that the postprime antibody responses
peaked at any time between weeks 2 to 8 and gradually declined by
week 10 in most animals for all antigens (Fig. 3). Not much dif-
ference was detected in the p32-, p54-, and pp62-specific IgG re-
sponses among the treatment groups (Fig. 3A to C). In contrast,
p72-specific IgG responses were highest in T3 animals, slightly
lower in T2 animals, and the lowest in T1 vaccinees (Fig. 3D). One
animal in the control group, T4, had high anti-p72 IgM and IgG
responses at week 1, but these responses were not detected in the
subsequent weeks, suggesting that the response at week 1 was non-
specific and not necessarily primed by the immunization (Fig. 2D
and 3D). In addition, adenovirus vector-specific IgG responses
were generally consistent with the ASFV antigen-specific IgG
responses (see Fig. S2 in the supplemental material). Overall,
postprime antibody response data clearly showed the ability of the
vaccine cocktail to rapidly induce ASFV-specific IgM and IgG re-
sponses in all vaccinees following single-dose inoculation (Fig. 2
and 3).
(ii) Postboost response. The gradual increase in antigen- and
vector-specific antibody titers up to 8 weeks postpriming was an
unexpected result and was a critical determinant with respect to
the administration of the boost dose at week 14 in order to reduce
any impact due to existing adenovirus-specific antibodies. Fol-
lowing boosting, robust antigen-specific recall IgG responses
against all four antigens were detected in serum collected at weeks
1 to 4 postboost (see Fig. S3 in the supplemental material). Eval-
uation of antigen-specific endpoint titers by ELISA in serum col-
lected at week 1 postboost showed that all vaccinees (groups T1 to
T3), but none of the sham-treated controls (group T4), had high
antibody titers against each antigen (Fig. 4). Among the four
ASFV antigens, pp62-specific titers were the highest, and the p72-
specific titers were the lowest (approximately 103 times lower)
(Fig. 4). Convalescent-phase serum ASFV antigen-specific titers
were also evaluated. The majority of vaccinees had p32- and p54-
specific titers that were equivalent to or higher than those in con-
valescent-phase serum (Fig. 4A and B), whereas for pp62 only T3
animals had titers equal to or higher than the convalescent-phase
serum titer (Fig. 4C). However, in contrast, p72-specific titers in
convalescent-phase serum were higher than those of the vaccinees
in groups T1 to T3 (Fig. 4D). A multiple comparison of antigen-
specific titers between the three treatment groups showed a signif-
icant difference only for pp62, with T3 titers significantly higher
than those of both T1 (P
 0.01) and T2 (P
 0.001) (Fig. 4C). A
comparison of preboost and postboost ASFV antigen-specific an-
tibody responses showed that boosting with the cognate priming
dose and adjuvant effectively amplified the primary response, re-
sulting in high antibody titers postboost (Fig. 4; see also Fig. S3).
Importantly, that the two-dose immunization with the Ad-ASFV
multiantigen cocktail induced titers comparable to those of the
ASFV-specific convalescent-phase serum clearly demonstrates the
ability of the multiantigen cocktail formulations to elicit very
strong immune responses.
A critical role for antibodies in protection against ASFV has not
been clearly established. Partial to complete protection has been
reported following immunization of pigs with a combination of
FIG 3 Antigen-specific serum IgG profiles postpriming. Antigen-specific IgGs were monitored biweekly postprime up to week 10 by ELISA. The absorbance
values at 450 nm across weeks 2, 4, 6, 8, and 10 postpriming for each animal are depicted using a color gradient where the lightest shade (first bar) represents week
2 and the darkest shade (last bar) represents week 10. Error bars show standard deviations among triplicate absorbance values. T4, negative control.
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recombinant subunit p30 and p54 antigens (23). In addition,
complete protection was reported in another study in which swine
were immunized with recombinant CD2v (HA) and then chal-
lenged with wild-type ASFV (39). However, in a separate study,
antibodies induced following a combination of recombinant sub-
unit p22, p30, p54, and p72 antigens did not provide sufficient
protection (24). Furthermore, an immunization strategy to avoid
ASFV-specific antibody responses by genetic fusion of recombi-
nant subunit p30, p54, and CD2v antigens to ubiquitin conferred
protection against lethal challenge in a proportion of vaccinees
(15). These disparate findings have not allowed the protective role
of host antibodies, if any, to be clearly defined during virulent ASF
infection. A protective role for antibodies in ASFV is strongly sup-
ported by the observation that passive immunization with anti-
ASFV serum confers complete protection against a subsequent
lethal challenge (40). Results in the present study using an Ad-
ASFV multivalent cocktail formulated in two different adjuvants
and administered in a prime-boost regimen induced detectable
antibody titers in 100% of immunized pigs and against each of the
four ASFV antigens.
Ad-ASFV multiantigen cocktail-primed antibodies recog-
nized ASF virus. Indirect fluorescence antibody (IFA) assay and
Western blot analysis using serum from week 1 postboost con-
firmed that antibodies induced by the experimental Ad-ASFV
multiantigen cocktail recognized intact, native ASFV. All Ad-
ASFV multiantigen cocktail-immunized swine, but none of the
sham-treated controls, had a strong IFA signal against primary
swine macrophages infected with the ASFV Georgia 2007/1 isolate
(Fig. 5A). Overall IFA results strongly demonstrated that the Ad-
ASFV multiantigen cocktail induced authentic ASFV-specific an-
tibody responses (Table 2). This outcome was also confirmed by
Western blotting using lysates from Vero cells infected with the
ASFV Georgia 2007/1 isolate. Sera from all the three treatment
groups (T1 to T3), but not the control group (T4), strongly rec-
ognized the ASFV antigens (Fig. 5B). A control Western blot per-
formed using mock-infected Vero cell lysate showed no back-
ground reactivity against host cell antigens (see Fig. S4 in the
supplemental material). It is important to note that these results
do not suggest that the primed antibodies can neutralize ASFV;
however, they do confirm that the synthetic genes used to generate
the Ad-ASFV constructs expressed authentic antigens.
Ad5-ASFVmultiantigen cocktail-primed antigen-specific IFN-
-secreting cells. ASFV antigen-specific IFN--secreting cells were
detected in whole peripheral blood mononuclear cells (PBMCs)
postpriming and postboost by IFN- ELISPOT assays (Fig. 6).
Postpriming, the majority of pigs in the three treatment groups
(T1 to T3) had higher IFN- responses against p54 and pp62
antigens than to p32 and p72 antigens. Notably, the p54-specific
IFN- responses were significantly higher in T1 pigs (P 
 0.05)
and in T2 pigs (P 
 0.01) than in the T4 sham-treated controls
(Fig. 6A). In addition, pp62-specific IFN- responses were signif-
icantly higher in T2 pigs (P
 0.001) than in the T4 controls (Fig.
6A). Antigen-specific IFN- recall responses observed in PBMCs
at 3 weeks postboost, most notably the p32- and p72-specific re-
FIG 4 ASFV-specific endpoint antibody titers. Antigen-specific endpoint titers of serum collected week 1 postboost were determined by ELISA. The endpoint
dilution was determined to be the dilution at which the sample OD was higher than the OD of cognate prebleed plus 3 standard deviations. The lowest titer was
1:64 103 against p72, and some of the highest titers were as high as 1:16 106 against pp62. The ASFV-specific convalescent-phase serum was also titrated, and
the titer against each antigen is indicated by a red star. Sera from T4 animals showed no reactivity above background to any of the antigens (see Fig. S3 in the
supplemental material). The antigen-specific titers among the treatment groups were compared using ANOVA, followed by Tukey’s multiple-comparison test.
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sponses, highlighted the booster dose effect (Fig. 6B). Compared
to the T4 sham-treated controls, significantly higher (P 
 0.05)
IFN- responses against p32, pp62, and p72, but not p54, were
observed in T1 but not in T2 and T3 animals (Fig. 6B). Postboost,
T1 pigs had higher, detectable IFN- responses against all four
antigens tested than pigs in the other two treatment groups. This
result differs from the postprime results in which T2 immunized
pigs were overall the best responders (Fig. 6A and B). One possi-
bility for the discordant postprime and postboost results may be
the relatively high anti-adenovirus titers in T2 versus those of T1 at
the time of boost, which reduced the overall effectiveness of the
booster dose in T2.
ELISPOT assays performed at study termination (week 8 post-
boost) using isolated splenocytes confirmed the presence of
antigen-specific IFN--secreting memory cells. Notably, strong
IFN- responses against the four ASFV antigens were detected
(Fig. 7). Significantly higher p32-specific IFN- responses were
detected in T1 (P
 0.01) and T2 (P
 0.05) swine (Fig. 7) than in
the T4 controls. Significant (P 
 0.01) p54-specific IFN- re-
sponses were detected only in T1 animals, whereas significant
(P
 0.01) pp62-specific IFN- responses and (P
 0.05) p72-spe-
cific IFN- responses were detected only in T2 animals (Fig. 7).
A recent study using a BacMam system to express a p30-p54-
CD2v chimera reported partial protection upon sublethal chal-
lenge and a direct correlation between protection and induction of
ASFV-specific IFN- T cells (41). In this study, strong IFN-
peripheral and splenic tissue responses were elicited against each
antigen in the Ad-ASFV multiantigen cocktail in the majority
FIG 5 The Ad-ASFV multiantigen cocktail induced authentic ASFV-specific antibody responses. Indirect immunofluorescence antibody (IFA) assay and
Western blotting using serum from week 1 postboost were used to confirm whether antibodies induced by the experimental Ad-ASFV multiantigen cocktail
recognized ASFV-infected cells and ASFV-derived antigens. (A) Primary swine macrophages infected with the ASFV Georgia 2007/1 isolate and probed with
individual, representative sera from six vaccinated and three control animals. ASFV-specific convalescent-phase serum was used as the positive (ve) control,
whereas normal pig serum was used as the negative control. The overall results are summarized in Table 2. (B) Western blots of lysates from Vero cells infected
with the ASFV Georgia 2007/1 isolates, probed with sera from all animals. Lane 1, ASFV-specific convalescent-phase serum; lane 2, normal swine serum. The
serum was also tested on mock-infected Vero cell lysates to check for background reactivity against host cell antigens (see Fig. S4 in the supplemental material).
Immunogenicity of Adenovirus-Vectored ASFV Antigens
November 2016 Volume 23 Number 11 cvi.asm.org 895Clinical and Vaccine Immunology
 o
n
 Septem
ber 12, 2018 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
of immunized swine (groups T1 to T3) following prime-boost.
Taken together, the ASFV antigen-specific IFN- responses ob-
served in this immunogenicity study are promising and support
the need to evaluate their potential to confer protection in a chal-
lenge study.
Ad5-ASFV cocktail-primed antigen-specific CTLs. One round
of in vitro-restimulated PBMCs (T1 to T3) isolated 4 weeks post-
boost was shown to effectively lyse autologous skin fibroblast
transfectants in an ASFV antigen-specific manner at defined effec-
tor/target (E:T) ratios in 51Cr release assays (Fig. 8). Lytic activity
against autologous skin fibroblasts transfected with a construct
expressing an FMDV negative-control antigen remained at 20%
or less for all animals, thus validating that the lytic activity ob-
served against ASFV antigens can be attributed to ASFV antigen-
specific cytotoxic T lymphocytes (CTLs) and not nonspecific NK
cells (Fig. 8). Stimulation of the PBMCs for an additional round to
further enrich CTLs failed to increase CTL activity, possibly due to
activation-induced death of effectors. Among the immunized
FIG 6 ASFV antigen-specific IFN- responses postprime and postboost. The frequencies of antigen-specific IFN--secreting cells in PBMCs induced at 2 weeks
postprime (A) and 3 weeks postboost (B) were evaluated by IFN- ELISPOT assay. The mean response of treatment groups T1 to T3 was compared to the mean
response of the sham-treated control group (T4) using ANOVA, followed by Bonferroni’s multiple-comparison test. SFC, spot-forming cells.
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swine in groups T1 to T3, the level of antigen-specific lysis was
equivalent in the T1 and T3 groups and lower in the T2 group.
This result is consistent with the postboost observation discussed
earlier in which relatively higher anti-adenovirus titers in T2 than
in T1 at the time of boost may have reduced the overall effective-
ness to amplify the primed CD8 T cell responses. The heteroge-
neous CTL responses observed within the context of the study and
assay designs are consistent with expected outcomes from the out-
bred commercial pigs used. This study is the first to demonstrate
induction of ASFV antigen-specific CTL responses in commercial
swine using an Ad-ASFV multiantigen cocktail, but further eval-
uation in subsequent studies using ASFV-infected target cells will
be required.
Substantial evidence in published literature emphasizes the
importance of CTLs in protection against ASFV. Studies have
shown that ASFV-specific CTLs can be induced in swine infected
with live attenuated ASFV, and the primed CTLs were shown to be
responsible for clearance of infected cells (13). Higher propor-
tions of ASFV-specific CTLs expressing CD4 and high levels of
CD8 (CD4 CD8high) have been detected in immune swine that
are protected from clinical disease than in immune but clinically
diseased pigs, suggesting that these CTLs are required for disease
control (9). Furthermore, depletion of CD8 T cells in swine re-
sults in loss of protective immunity to ASFV infections (14).
Within this context, the CTL results reported here are noteworthy
and clearly demonstrate the ability of a replication-deficient virus-
vectored ASFV multiantigen cocktail to induce antigen-specific
CTLs that are capable of recognizing and lysing autologous ASFV
antigen-presenting fibroblasts.
Ad5-ASFV cocktail was well tolerated. Following inoculation
of the Ad-ASFV multiantigen cocktail, both the 1010 and the 1011
doses and adjuvant formulations (Table 1) were reasonably well
tolerated in all the swine. Although no adverse systemic effects or
injection site reactions were observed, some pigs in T1, T2, and T4
that received the ENABL formulation had mild injection site
swelling, were transiently depressed, and had reduced appetite for
2 days following the booster dose. T3 vaccinees (Zoetis adjuvant)
were active, but all had a pink discoloration at the injection site.
However, by the third day postboost, all the swine were active and
healthy with a good appetite and remained so for the rest of the
study period. Thus, overall, the Ad-ASFV multiantigen cocktails
formulated at both doses and with both adjuvants were safe and
well tolerated by all the swine.
Conclusions. The ASFV is a large complex DNA virus encod-
ing150 proteins. Experimental subunit vaccines based on a few
of these antigens have generated different protective outcomes,
demonstrating that these antigens do play some role in host pro-
tection. Immunization of animals with an expression library of
restriction enzyme-digested ASFV genome fragments protected
60% of the animals (42). This outcome suggests that protection
through subunit vaccines is feasible but is unlikely to be highly
efficacious using a single or only a few antigens. Empirical identi-
fication of antigens necessary for inducing a protective response,
along with a suitable antigen delivery system that elicits strong
cellular as well as humoral responses, may be a reasonable strategy
to develop an efficacious, prototype ASFV vaccine. The immuno-
genicity data generated from this proof-of-concept study showed
that the replication-deficient adenovirus vector, dose, adjuvant
formulation, and immunization regimen effectively induced
strong antibody (with unprecedented rapid isotype switching)
and cellular responses against four ASFV antigens. An analysis
of the overall differences in antibody and T cell immune re-
sponses observed across the three different treatment groups
revealed some interesting outcomes. In the case of the humoral
responses, the T3 animals (immunized with the Zoetis adju-
vant) had a slightly higher antibody response; however, the
endpoint titration data (Fig. 4) failed to demonstrate any sig-
nificant differences in the titers among the three treatment
FIG 7 ASFV antigen-specific IFN- recall responses in spleen. The presence of antigen-specific IFN--secreting memory T cells in the spleen at study
termination (week 8 postboost) was evaluated by IFN- ELISPOT assay. Statistical analysis was done as described in the legend of Fig. 6.
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groups for three of the four ASFV antigens tested (pp62 was the
only exception). With respect to T cell-mediated immune re-
sponses, the postprime antigen-specific IFN- response clearly
showed that T2 (high dose; ENABL adjuvant) animals were the
best overall responders. However, the postboost data suggest
that the low-dose prime and low-dose boost group (T1) had the
highest recall response. Based on this outcome, it may be useful
in future immunogenicity and efficacy studies to test whether
priming with the low dose (1010 IFU/Ad-ASFV construct) and
boosting with the high dose (1011 IFU/Ad-ASFV construct) will
elicit better immune responses. In addition, there is merit to test-
ing both adjuvants in future efficacy studies to better understand
the relevance of the varied immune responses induced in the con-
text of the protection conferred.
In conclusion, an Ad-ASFV multiantigen cocktail two-dose for-
mulation was immunogenic and safe when administered in a prime-
boost regimen. Results showed evidence of rapid postprime antibody
class switching, induction of robust antibody responses which rec-
ognize ASFV-infected cells, and the generation of antigen-specific
IFN- and antigen-specific CTL responses to all four ASFV anti-
gens. The immunogenicity data from this study validate our ap-
proach of using an adenovirus-vectored cocktail of ASFV antigens
and set the stage for conducting future challenge studies using a
cocktail of the above antigens as well as other novel ASFV anti-
gens. Collectively, these data validate a synthetic gene-based ap-
proach to generate ASFV antigen delivery constructs and provide
a rational strategy for further screening of ASFV antigen targets
toward development of a multiantigen, efficacious ASF vaccine
FIG 8 Ad5-ASFV multiantigen cocktail-primed ASFV antigen-specific cytotoxic T lymphocyte (CTL) responses. Antigen-specific CTL responses in PBMCs
collected postboost (week 4) were evaluated at effector-to-target ratios of 50:1 and 25:1 using a standard 51Cr release assay. Data are represented as the percent
specific lysis against each ASFV antigen and an FMDV negative-control antigen. Representative data for 2 animals from treatment groups T1, T2, and T3 are
shown. Assays were not conducted for animals from the control group, T4. Ag, antigen.
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that is able to differentiate infected from vaccinated animals
(DIVA vaccine).
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